Sana Biotechnology, Inc. (SANA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.63
- As of
Kresmion compiles this page from SANA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Sana Biotechnology, Inc. (SANA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
See the full SANA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SANA on one page. Preview it with sample data, then open it live with a free account.
Preview the SANA dossierActive events for SANA
- mediumEarnings above estimates
Q2-2026: Beat consensus by 12.6%, EPS $-0.13 vs $-0.1487 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +93% to SANA (2026Q2)
- medium13F: new position
Point72 Asset Management, L.P. new position in SANA
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 59% of SANA (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +155% to SANA (2026Q1)
FREE, NO ACCOUNT
Every event on SANA, as it fires
You are seeing 5 of 7 events recorded on SANA since 2026-06-03.
The five above landed across 3 days. The other 2 were recorded on 1 other days. 4 of the 7 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SANA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 799566104 · 2026Q2 | $4.3M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 799566104 · 2026Q2 | $2.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 799566104 · 2026Q2 | $2.2M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 799566104 · 2026Q2 | $2.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 799566104 · 2026Q2 | $563K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 799566104 · 2026Q2 | $140K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SANA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SANA against its peers
SANA's return on equity of -151.8% ranks in the 12th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | SANA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 28.4M | n/a | 10 |
| Operating margin | n/a | -98.2% | n/a | 9 |
| Net margin | n/a | -101.1% | n/a | 9 |
| Return on equity | -151.8% | -44.8% | 12 | 20 |
Peers (20): XOMA.D, ANNX, SGMT, IMMX, GERN, ACHV, PRME, HELP, DSGN, NVCT, AURA, ABUS, BCAX, SLDB, LXRX, ARDX, GYRE, WVE, DBVT, CRMD. Left out: IAM (no annual filing), ANL (period gap), ATTO (no annual filing), APMD (no annual filing), ODTX (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (SANA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SANA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SANA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.